The Top 5 Priorities for Early-Stage and Scaling Life Science Companies – According to Investors and Non-Execs

As a talent search practice in life sciences and technology we worked with many organisations going through start up, scale up and exit and we’ve had a ring side seat when it comes to investors and non-executives and their views on what makes them sit up and take notice. Here’re some of the observations we’ve gleaned over the years from them.

The UK’s life science sector is bursting with innovation — from breakthrough therapeutics to enabling technologies that transform research and patient care. But great science alone isn’t enough to scale successfully.

If you ask seasoned non-executives and active investors what separates the companies that thrive from those that stall, they’ll often give the same answer: it’s about building the right commercial, operational, and strategic foundations early.

Here are the five priorities they consistently look for when judging whether a life science venture is on the right track.

1. A Clear and Credible Route to Market

It’s tempting to keep the focus on the science — after all, that’s your passion and your differentiator. But investors want to see exactly how you’ll translate the innovation into revenue.

That means:

  • A well-defined target market and customer profile.
  • A go-to-market strategy that accounts for regulatory requirements, adoption barriers, and procurement cycles.
  • An understanding of the competitive landscape and how you’ll win share.

Investor perspective: A groundbreaking platform without a plan to monetise is just an academic project. Market access and adoption pathways should be embedded into the strategy from day one.

2. Strong, Commercially Minded Leadership

In early-stage science-led companies, the founding team is often deeply technical. That’s a strength — but scaling demands commercial experience at the top table.

Investors favour leadership teams that blend:

  • Scientific authority with commercial acumen.
  • Proven track records in sales, licensing, or partnerships.
  • The ability to make difficult, market-driven decisions.

Investor perspective: A great CEO in life sciences is part scientist, part strategist, part dealmaker.

3. Evidence of Early Traction

Even pre-revenue, investors and non-execs look for proof points that your proposition works in the real world. This could be:

  • Pilot studies or early clinical data.
  • Letters of intent or MOUs from potential customers or partners.
  • Strong inbound interest from key market players.
  • Grant wins or funded collaborations.

Investor perspective: Traction is the bridge between the lab and the market. It signals demand and reduces perceived risk.

4. Robust Financial Discipline

Cash is oxygen. Scaling life science companies need a clear understanding of burn rate, runway, and funding strategy.

That means:

  • Regular financial forecasting tied to strategic milestones.
  • Understanding the link between cash spend and value creation.
  • Clear, realistic fundraising plans.

Investor perspective: “Show me you can deploy capital efficiently, and I’ll show you I can help you raise more.”

5. A Scalable Operating Model

Scaling isn’t just about selling more — it’s about being ready to deliver at scale without breaking the business.

Investors look for:

  • Early investment in quality systems and compliance.
  • Repeatable processes for R&D, manufacturing, and customer delivery.
  • The right people in the right seats, with gaps identified and plans to fill them.

Investor perspective: A company that can’t scale operations will see its growth stall, no matter how good the science or the market fit.

In Conclusion

In the high-stakes, capital-intensive world of life sciences, investors and non-executives want confidence that their capital and expertise will accelerate—not rescue—the business.

The most successful early-stage and scaling companies in the UK are the ones that:

  1. Know their market.
  2. Build balanced, capable leadership teams.
  3. Prove their proposition early.
  4. Run a tight financial ship.
  5. Lay the operational foundations for scale.

Get this right, and you won’t just attract investment—you’ll keep it.

Ewan Jardine is Managing Director of Kleboe Jardine Ltd, based in Edinburgh and has worked for 35 years building startups and scale ups in life Science and Technology.

Why Hiring Your First Sales Professional in a Life Sciences Startup Is So Tough – and How Founders Can Avoid Missteps

I’m often in conversation with Founders, CEO’s and Non Execs who have navigated this both successfully and badly in fairness so here’s some of the feedback.

Launching a life sciences company—with its complex science, regulatory hurdles, and long development cycles—is challenging enough. Layer on the added pressure of hiring your first sales professional, and you’re navigating unfamiliar territory: one where assumptions and instincts may lead you astray. Here’s why it’s so hard, how it can go wrong, and how founders can proactively steer clear of common traps.

1. The Unique Hiring Psychology at Play

Role ambiguity and founder inexperience. Founders entering commercial realms for the first time often lack a clear mental model of what a life sciences sales hire truly needs to excel. Without previous experience in recruiting or leading salespeople, you’re less able to assess candidates effectively—and more prone to biases or misplaced confidence LinkedIn+3Reddit+3First Round+3.

“We don’t know what we don’t know.” In unfamiliar domains, founders may overvalue credentials or industry buzzwords, rather than the traits that matter: adaptability, affinity for ambiguity, and hustle.

Psychological mismatch. Founders are typically exploratory and innovation-driven—they thrive on novelty and high autonomy SineWave Ventures+15Nature+15LinkedIn+15. In contrast, effective salespeople—particularly in life sciences—need structure, process discipline, resilience, and the ability to communicate technical complexity clearly.

2. Common Pitfalls & Poor Outcomes

  1. Hiring too early (when processes aren’t ready) Adding a sales hire before you’ve validated product–market fit or defined repeatable sales steps sets them up to fail. You’re simultaneously testing the candidate, your process, and your market appeal—all at once First Round.
  2. Picking the wrong profile High-profile industry veterans (Mistake #1) may lack the “roll-up-your-sleeves” mentality critical in early-stage ventures onstartups.com. Conversely, candidates without scientific fluency may stumble in life sciences sales, where articulating complex medical/device details to clinicians or researchers is essential seclifesciences.com.
  3. Climate mismatch and culture clash Sales professionals accustomed to enterprise environments may struggle in startups with limited resources and shifting priorities Activated Scale.
  4. Transactional hiring with no self-reflection Founders who avoid founder-led sales deprive themselves of learning opportunities, while also signaling disinterest or overconfidence. This disconnect can deter good hires and distort expectations Wikipediaforumvc.com+1.
  5. Founder’s syndrome / founder overreach When founders are reluctant to step back, they micromanage or override the sales team, preventing them from owning the role Nature+8Wikipedia+8forumvc.com+8.

3. How to Avoid These Traps

Self-Reflect First

  • Are you suited to do sales yourself? If not, get honest about your limitations: do you enjoy persuasion? Can you handle rejection? Do you have the patience to simplify complex concepts?
  • Understand that life sciences sales require curiosity, persistence, technical fluency—and the emotional stamina to persevere.

Do Founder-Led Sales Before Hiring

  • Close 10–20 deals yourself. This gives you firsthand insight into the timeline, objections, decision-makers, and product positioning The Timesseclifesciences.comSaaStr+2forumvc.com+2.
  • Keep notes: your ICP (ideal customer profile), typical objections, sales cycle length, and discovery processes. This becomes the training scaffold for your hire First Round.

Wait for Sales Momentum

  • Only hire when you have early traction or repeatable signals (even if imperfect). This minimizes guesswork and improves candidate fit First Round.

Hire the Right Profile

  • Prioritize adaptability, grit, and ability to learn over “perfect” domain pedigree.
  • Ideally hire from adjacent scientific disciplines—even academic backgrounds—so they can translate complex ideas credibly and quickly First Round.

Use Structured Hiring Tools

  • Incorporate pre‑hire assessments to evaluate alignment of cognitive ability and personality with the demands of a start‑up sales role Wikipedia.

Start with Fractional or Part-Time Sales Support

  • Tap into fractional sales professionals who bring industry-savvy without long-term cost commitment Activated Scale.

Plan for Transition & Scale

  • Aim to hire two salespeople, not one—this allows comparison and avoids vanity hires SaaStr.
  • Establish clear metrics and training from Day One The Times.

4. Managing Investors & Stakeholder Expectations

Acknowledge the learning curve.

  1. Demonstrate that you did your due diligence—founder-led selling, documenting patterns, and validating hypothesis. This builds credibility.
  2. Frame hiring as strategic: “We’re investing in capability to scale, but only once we’ve built the foundation.”

Position yourself as an enabler, not a default hire.

  • Show self-awareness: “My strength is in R&D and vision, not direct selling. We need someone with that muscle to scale.”
  • Offer oversight without overreach: set scorecards, advise on strategy, but don’t micromanage. Let them own the role.

Use pilot structures or probationary periods to de-risk hires—especially in early financing stages.

5. The Science and Psychology Behind It

  • Personality Diversity Matters Founders often exemplify high openness, energy, and novelty-seeking traits—but successful startups benefit from complementary profiles: pragmatic executors, disciplined closers, process builders arXiv+14First Round+14forumvc.com+14Activated ScaleReddit+7Nature+7onstartups.com+7.
  • Overconfidence Bias Overconfidence may feel empowering—but it can cloud judgment about your hiring readiness or your own fit in sales The Times.
  • Learning Dynamics and Failure Trajectories Startup success often hinges on learning from early failures. Founders who experiment, learn, and iterate (e.g. in sales) are more likely to progress than those stuck in random search or overreliance on instincts. arXiv.

In Summary

Hiring your first sales professional in life sciences is a pivotal and sensitive inflection point. Avoid the temptation to default to hire too early, or to assume the founder is the best salesperson. Instead, practice self-awareness, validate through founder-led sales, lean on structured tools, and hire thoughtfully—when signals are strong. Manage investors with clarity about your strategy and focus on building a complementary team that balances your traits with executional strength.

Can a UK life sciences start-up succeed in 2025? The odds, the traps, and how to tilt the table

The short answer

  • There isn’t a single official “life-sciences startup failure rate” for the UK. As a proxy, the Office for National Statistics shows 39.4% of UK businesses survive five years—so ~60.6% fail within five years (all sectors). Life sciences add extra technical and regulatory risk on top of that baseline. Office for National Statistics
  • The funding climate is better than 2023 but still selective: UK biotech raised £3.5bn in 2024 (up 94% YoY) and £1.23bn in H1 2025, yet investors remain choosy and much of the capital is international. Layoffs continue sector-wide.
  • Technically, drug programs are inherently risky: ~7.9% of assets that enter Phase 1 ever reach approval (global). If your company rides on a single asset, that probability drives company risk. Biotechnology Innovation Organization

So…what are your real chances?

Baseline: Treat ~40% five-year survival as a rough economy-wide benchmark. For a therapeutics startup tied to one or two clinical assets, the probability of product success (and ability to keep financing) often makes the company’s odds worse than the macro baseline—unless you spread risk (multiple shots on goal), de-risk early, and manage runway tightly. UK capital is available, but access is uneven and still “risk-off” for many investors. Office for National Statistics

The 5 biggest reasons UK life sciences startups fail

  1. They run out of cash before value-inflecting data Fundraising cycles lengthened; down/flat rounds are common; public markets remain choppy and selective. Even strong companies have faced layoffs while waiting for data or market windows to reopen. The Wall Street JournalFierce Biotech
  2. Technical/clinical attrition (“the experiment said no”) Great science still fails often—only ~7.9% of Phase-1 programs make it to approval; Phase 2 is the biggest kill-zone. Investors routinely stress “good failures” (right de-risking experiments) vs. sloppy ones. go.bio.org
  3. Regulatory & market-access friction The UK has improved MHRA speed via International Recognition Procedure (IRP)and NICE has beefed up advice services, but many startups still under-resource regulatory/HTA strategy and NHS adoption planning.
  4. Team gaps and mis-hiring Founders may underweight experienced operators in CMC, clinical, regulatory and commercial. As one investor put it, failures often come from risks “around people, markets, timelines or cash management,” not just science.
  5. Go-to-market & reimbursement misalignment Evidence packages miss payer needs; NHS pathways are engaged too late; pricing/value communication is weak—especially outside therapeutics (Dx, digital, medtech). Houlihan Lokey

5 moves that materially improve your odds (UK-specific where it matters)

  1. Hire the right people—early—and build a grown-up board Bring in leaders who’ve shipped in your modality: CMC/quality for biologics/ATMPs; clinical operations that can run UK/EU studies; a regulatory head who knows MHRA, IRP and NICE Advice; and a commercial/NHS market-access lead (for Dx/medtech/digital). Investors consistently back experienced teams; Syncona explicitly highlights execution/leadership as a determinant in portfolio outcomes, and even steps in to change CEOs when needed. Syncona
  2. Design “killer experiments” and staged financing Map the fewest, fastest experiments that answer the value-defining questions (target, mechanism, tox, manufacturability, payer-relevant endpoints). Celebrate “good failures” that stop burn early; reserve cash for the next best shot. Labiotech.eu
  3. Get proactive on regulation and market access from Day 0
  • Use MHRA’s IRPwhere appropriate to leverage approvals from trusted regulators and speed time to UK authorisation.
  • Book NICE Advice to align evidence with HTA and NHS adoption before pivotal studies. NICE
  • Work with the Health Innovation Network (the 15 regional bodies formerly AHSNs) to pilot and scale inside the NHS. The Health Innovation Network –
  1. Plan capital like a pessimist: 18–24 months runway to the next binary Triangulate with grant and non-dilutive routes (Biomedical Catalyst etc.), but assume single-digit success rates for competitive grants—helpful when they land, not a plan you bet the company on.
  2. Ride the UK’s “selective strength” in 2025 The UK raised £3.5bn in 2024 and £1.23bn in H1 2025; much is international capital with a bias toward experienced teams and clear, capital-efficient paths. Tailor your story to that reality: milestone-driven use of proceeds, realistic valuations, and syndicates that can follow on. As Syncona’s CEO put it this year, volatile markets and access-to-capital headwinds persist, so control what you can—execution and burn. BioIndustry Association+2BioIndustry Association+2Syncona

Voices from investors & sector leaders (why this all matters)

  • Sir John Bell warns the UK risks losing momentum without deeper capital and scale-up focus—despite world-class science and talent. The Times
  • BIA data show investment is “holding firm” in 2025, yet a significant share is non-UK VC, underscoring the need to appeal to global investors and to strengthen domestic pools. pharmaphorum
  • Kate Bingham has highlighted how a collaborative, enabling regulator accelerates translation—now echoed by MHRA’s IRP. Build your plan to exploit that tailwind. NHS

Bottom line for founders (and their boards)

  • Your base case (absent special advantages) is battling a ~60% five-year failure rate seen across UK businesses. Life sciences adds technical risk: most drug programs do not succeed. Office for National Statistics
  • But 2024–25 UK capital is available for credible teams with crisp milestones, de-risked plans, and NHS-savvy market access strategies. Craft your experiments, your runway, and your hiring around that reality. BioIndustry Association+1

If you’re scaling a business and would like advice and insight particularly in hiring the right people early then connect with me here on LinkedIn and we’ll start a conversation.

Ewan Jardine, Kleboe Jardine Ltd

Biotech companies across the UK often find stability elusive due to frequent turnover in critical roles

Biotech companies across the UK often find stability elusive due to frequent turnover in critical roles, which hinders growth. Imagine a future where your workforce is cohesive and turnover is minimal, allowing innovation to flourish.

The gap between current challenges and this aspirational future often lies in recruitment strategies that don’t align with company goals.

By focusing on candidate services aimed at career transformation and fit, we can guide you towards achieving this stable and dynamic workforce.

Exciting times for the biotech industry!

Exciting times for the biotech industry! A Technavio report projects a USD 805.6 billion expansion from 2025-2029, driven by innovative vendors and transformative AI applications.

AI is reshaping sectors like genetic engineering and precision medicine—key areas where Kleboe Jardine guides C-Suite executives in achieving strategic growth.

Read more here.

Scaling operations efficiently in biotech startups

Scaling operations efficiently in biotech startups often feels elusive due to the scarcity of specialised professionals needed for key roles. This difficulty in staffing the right expertise can hamper growth and operational effectiveness.

Looking ahead, imagine a thriving environment where growth is sustained by a strong and skilled talent pool, supporting seamless scaling processes. This isn’t just a vision—it’s an achievable reality.

The main challenge is accessing tailored talent acquisition strategies that address specific needs. This is where strategic acquisition services come into play, offering solutions that bridge the gap between current hurdles and future success.

Through specialised services designed for transformation and growth, your startup can secure the expertise required to drive progress. Discover how these services can help shape your journey to a more effective and scalable future.

UK firms face a pivotal challenge—revolutionising their innovation processes

In today’s complex biotech arena, UK firms face a pivotal challenge—revolutionising their innovation processes. With an ideal goal of enhancing their capabilities, they find themselves hindered by the difficulty of sourcing experts in niche fields.

This lack of access stifles growth, leaving businesses yearning for a vibrant future powered by leading-edge talent. Exploring the right recruitment strategies focused on Medical Devices, Biotechnology, and Bioinformatics can propel companies into this desired future, ensuring competitive advantage.

At Kleboe Jardine, our expertise in targeted recruitment can pave the way toward this vision. Elevate your innovation capabilities by connecting with the right professionals.

High turnover rates are disrupting project continuity in biotech startups

High turnover rates are disrupting project continuity in biotech startups, leading to productivity setbacks. This challenge often stems from a mismatch between a company’s needs and candidate skills or cultural fit.

Envision a scenario where your teams are stable, with low turnover, ensuring consistent and efficient project outcomes. The key is aligning your recruitment strategy to focus on candidates who not only possess the requisite skills but also harmonise with your company culture.

Personalised recruitment services can bridge this gap effectively, paving the way for long-term project success.

The UK government’s new life sciences strategy,

The UK government’s new life sciences strategy, aimed at enhancing R&D and expediting medicine regulation, has sparked both support and concern within the pharmaceutical sector.

While GSK and Moderna have welcomed the initiative, unresolved drug pricing issues threaten to dampen the UK’s competitive edge, a concern shared by many industry leaders.

At Kleboe Jardine, we understand how critical supportive frameworks are for fostering growth and innovation. Let’s continue the conversation on how we can collectively drive progress in life sciences.

Read more here.

10 Signs your scale up is crushing your culture

Introduction: Scaling up a company can bring about exciting growth opportunities and increased success. However, as organizations expand rapidly, it’s crucial to pay attention to the impact on the company’s culture. A scale-up can inadvertently crack or damage the culture that once thrived within the organization. In this blog post, we’ll explore ten signs that your scale-up has negatively affected your company culture.

  1. Loss of Core Values: When a company scales up quickly, there’s a risk of diluting or losing sight of its core values. If employees no longer prioritize or embody these values, it’s a clear sign that the culture has been compromised. https://www.forbes.com/sites/curtsteinhorst/2019/10/17/rethinking-the-value-of-core-values/?sh=37505231a042
  2. Increased Politics and Bureaucracy: As organizations grow, layers of bureaucracy can develop, leading to a rise in office politics. If decision-making becomes convoluted, and employees spend more time navigating internal politics rather than focusing on their work, it indicates a culture shift. https://sloanreview.mit.edu/article/politics-in-the-workplace-how-can-managers-keep-the-peace/
  3. Lack of Communication and Transparency: In a healthy company culture, open communication and transparency are essential. If there is a noticeable decline in the flow of information, frequent miscommunications, or secretive decision-making processes, it suggests that the culture has suffered as a result of scaling up. https://extension.psu.edu/effective-communication-in-the-workplace
  4. Decreased Employee Engagement and Satisfaction – & Higher staff turnover: A positive culture fosters high employee engagement and satisfaction. However, if you observe a decline in enthusiasm, increased employee turnover, or decreased morale, it’s a sign that the scale-up has negatively impacted the working environment. https://kleboejardine.com/employee-turnover-web-calculator/
  5. Decline in Innovation and Creativity: A cracked culture may stifle innovation and creativity within the organization. When employees feel overwhelmed by increased workload or restricted by rigid processes, they may hesitate to propose new ideas or take risks.
  6. Fragmented Teams and Siloed Departments: In a scale-up, teams and departments may become isolated from one another, hindering collaboration and creating silos. If communication and cooperation between teams have deteriorated, it indicates a cultural breakdown.
  7. Resistance to Change: Change is an inevitable part of scaling up, but a damaged culture may result in resistance to change from employees. If there is a prevailing reluctance to embrace new initiatives or adapt to evolving market conditions, it suggests that the culture has been negatively impacted. https://www.forbes.com/sites/forbescoachescouncil/2017/12/11/12-ways-to-overcome-your-resistance-to-change/?sh=74f34a7f5833
  8. Erosion of Trust: Trust is the foundation of a healthy work culture. If trust levels decline, employees may become suspicious or hesitant to rely on their colleagues or leadership. Lack of trust can lead to decreased productivity, increased conflicts, and overall dissatisfaction.
  9. Misalignment of Goals and Priorities: As a company grows, the alignment of goals and priorities can become misaligned. If different departments or teams pursue conflicting objectives, it creates a fragmented culture and hinders collective progress.
  10. Leadership Vacuum: When an organization scales up rapidly, there is a risk of a leadership vacuum. If leaders fail to adapt to the changing needs of the organization or are unable to effectively communicate the company’s vision, it can lead to confusion and a breakdown in the culture. https://www.news24.com/fin24/opinion/opinion-leadership-vacuum-holding-out-for-a-hero-is-part-of-the-problem-20230514

Recognizing the signs that your scale-up has cracked your culture is crucial for addressing and rectifying the issues at hand. By proactively focusing on strengthening your company’s culture during the growth phase, you can ensure that the organization retains its core values and provides a supportive environment for employees to thrive. Remember, a healthy culture is vital for long-term success, and it requires continuous attention and investment.

When you need some help in scaling your business, look no further than Kleboe Jardine. We’re experts in Life Sciences & Tech Scale up. Ewan – ej@kleboejardine.com or 07958 676 202